| pubmed-article:15962104 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15962104 | lifeskim:mentions | umls-concept:C0027059 | lld:lifeskim |
| pubmed-article:15962104 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:15962104 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:15962104 | lifeskim:mentions | umls-concept:C0041215 | lld:lifeskim |
| pubmed-article:15962104 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:15962104 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:15962104 | pubmed:dateCreated | 2005-6-17 | lld:pubmed |
| pubmed-article:15962104 | pubmed:abstractText | The comprehension of the pathogenesis of Trypanosoma cruzi-elicited myocarditis is crucial to delineate new therapeutic strategies aiming to ameliorate the inflammation that leads to heart dysfunction, without hampering parasite control. The augmented expression of CCL5/RANTES and CCL3/MIP-1alpha, and their receptor CCR5, in the heart of T. cruzi-infected mice suggests a role for CC-chemokines and their receptors in the pathogenesis of T. cruzi-elicited myocarditis. Herein, we discuss our recent results using a CC-chemokine receptor inhibitor (Met-RANTES), showing the participation of CC-chemokines in T. cruzi infection and unraveling CC-chemokine receptors as an attractive therapeutic target for further evaluation in Chagas disease. | lld:pubmed |
| pubmed-article:15962104 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15962104 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15962104 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15962104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15962104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15962104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15962104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15962104 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15962104 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15962104 | pubmed:issn | 0074-0276 | lld:pubmed |
| pubmed-article:15962104 | pubmed:author | pubmed-author:TeixeiraM MMM | lld:pubmed |
| pubmed-article:15962104 | pubmed:author | pubmed-author:Lannes-Vieira... | lld:pubmed |
| pubmed-article:15962104 | pubmed:author | pubmed-author:SilvaA AAA | lld:pubmed |
| pubmed-article:15962104 | pubmed:author | pubmed-author:MarinoA P M... | lld:pubmed |
| pubmed-article:15962104 | pubmed:author | pubmed-author:SantosP V APV | lld:pubmed |
| pubmed-article:15962104 | pubmed:author | pubmed-author:PintoL M OLM | lld:pubmed |
| pubmed-article:15962104 | pubmed:author | pubmed-author:GazinelliR... | lld:pubmed |
| pubmed-article:15962104 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15962104 | pubmed:volume | 100 Suppl 1 | lld:pubmed |
| pubmed-article:15962104 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15962104 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15962104 | pubmed:pagination | 93-6 | lld:pubmed |
| pubmed-article:15962104 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:meshHeading | pubmed-meshheading:15962104... | lld:pubmed |
| pubmed-article:15962104 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15962104 | pubmed:articleTitle | CC-chemokine receptors: a potential therapeutic target for Trypanosoma cruzi-elicited myocarditis. | lld:pubmed |
| pubmed-article:15962104 | pubmed:affiliation | Laboratório de Autoimunidade e Imuno-regulação, Departamento de Imunologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, 21040-900, Brasil. | lld:pubmed |
| pubmed-article:15962104 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15962104 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
